Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D and Innate Responses: Recognition, Peptides and Function: Full Evidence Review

Previous related pageVitamin D and Innate Responses: Recognition, Peptides and Function: Study SummaryNext related pageChildhood Vitamin D, Immune Development and Neurodevelopment: Full Evidence Review
Study at a glance

What was studied?

Researchers asked how vitamin D affects early immune responses. They examined human cells, tissue samples and small human studies. They measured recognition signals, small defence proteins and laboratory defence activity. These measurements answer different questions.

What did the studies find?

Vitamin D changed selected immune signals, but the direction differed between cell types. Some experiments found increased defence-related signals. Other experiments found reduced signals. Raising vitamin D in people did not consistently increase measured defence proteins or improve laboratory defence activity.

What does this mean?

A change in a gene signal does not necessarily mean more working protein is present. More measured protein does not necessarily mean better defence. Blood measurements may also differ from measurements taken at a body surface, such as the airways.

What are the limits?

Several human studies were small, lacked a comparison group or analysed only some participants. These studies do not establish a single vitamin D blood level that controls immune activation. They do not prove that taking supplements prevents infection, and they do not provide a personal dose recommendation.

Read the full article below ↓

Vitamin D can alter selected innate immune responses, but the direction and meaning depend on the cell, stimulus and measurement. This review compares ten studies of recognition responses and antimicrobial peptides, separating gene activity, protein abundance, laboratory defence and clinical outcomes. Its central question is whether a change at one stage establishes a change at the next. For the shorter account, read Vitamin D and Innate Responses: Recognition, Peptides and Function: Study Summary.

Recognition, activation and defence are different stages

Innate immunity includes rapid recognition and response systems in immune cells and body surfaces. Pattern-recognition receptors detect broad features associated with microbes or tissue damage. Their abundance is one measurement; the strength of a downstream signal is another. Whether a cell subsequently changes a defence function is a further question. The overview Vitamin D and Innate Immunity introduces these components without replacing direct evidence about their responses.

An activation threshold is the amount of stimulation needed to produce a defined response. Showing more receptor expression or a different response at a selected exposure does not establish a universal quantitative threshold. A blood vitamin D category is different again. None of the selected studies establishes one blood concentration that causally determines innate activation across cells and tissues. This distinction matters when interpreting the physiological idea of proportional responses discussed in Vitamin D and Immune Overactivation.

The studies also examine different forms of vitamin D. Some directly expose cells to calcitriol, the active hormone. Others supplement people and measure circulating 25-hydroxyvitamin D, a marker of vitamin D status. Local conversion, cell differentiation and concurrent signals affect the comparison. A cell experiment with active hormone cannot be translated directly into a supplement dose or a claim about clinical infection protection.

Co-signals and skin responses establish context

Liu and colleagues’ 2009 human-monocyte study examined how vitamin D receptor signalling and an inflammatory co-signal converged on antimicrobial programmes. The vitamin D receptor is a protein through which active vitamin D influences cellular responses. Selected defensin and cathelicidin responses had different signalling requirements. These two peptide families therefore could not be treated as interchangeable readouts of one general immune effect.

Expression and laboratory antimicrobial function were examined as separate outcomes. The experiment supports the importance of the surrounding signals, rather than a claim that vitamin D independently increases every defence pathway. Small donor experiments do not establish protection from infection in people. This work belongs to a related research programme containing earlier reports; shared investigators and potentially unreported donor overlap are not independent external replication.

Schauber and colleagues examined injury-associated responses in human skin, cultured skin cells and mouse comparisons. Human observations included a wound series of five people and a topical comparison involving seven. Selected recognition-receptor and cathelicidin responses increased in a vitamin D-related signalling context. The human and mouse findings also showed that cathelicidin regulation is not identical across species.

The skin findings illustrate a responsive epithelial setting, but they did not demonstrate fewer clinical wound infections. Nor did they measure a universal numerical activation threshold. Skin injury observations and cultured-cell mechanisms make complementary contributions within the same programme; they are not interchangeable clinical trials. The broader setting is explained in Vitamin D and Barrier Immunity, while this review focuses on what recognition and peptide measurements can establish.

Opposing cell responses prevent a universal direction claim

Kundu and colleagues compared several human mononuclear phagocyte cell types, a family that includes monocytes, macrophages and dendritic cells. Active vitamin D attenuated selected dendritic-cell signals, did not attenuate macrophage responses and enhanced selected monocyte responses. Those opposing directions are central findings, not inconvenient exceptions to a uniformly suppressive effect.

The accompanying clinical observations were small and uncontrolled, with signalling subsets of eight people per group. Baseline vitamin D status did not correlate with the activation indices in the reported comparison. A selected monocyte signalling response increased in the more-deficient subgroup after supplementation, but this does not establish a general clinical benefit or a response in all cell types. Hundreds of cellular measurements are not hundreds of independent human participants.

Jeong and colleagues provide a further contrasting skin-cell example. In cultured human keratinocytes, calcitriol attenuated selected stimulated receptor, peptide and inflammatory messenger transcripts. A transcript is a molecular message used in producing a protein; a transcript change need not produce an equal change in active protein. The work was mainly molecular, with unclear biological replicate counts and a timing discrepancy between methods and results.

The Jeong findings do not establish improved defence or treatment of a skin condition. They nevertheless qualify a universal claim that vitamin D always increases peptide expression in epithelial cells. Together with Kundu, they make the context-specific meaning of Vitamin D and Immune Modulation concrete: the observed direction depends on the response being measured, not merely on whether vitamin D is present.

Receptor abundance and downstream output can diverge

Ojaimi and colleagues followed a small group after vitamin D replacement without a placebo comparison. Table denominators were 16 at baseline, 15 at one month and 13 at three months. Important response analyses selected 11 responders, with nine available later. Receptor measurements and cytokine responses did not change in a uniform way. Cytokines are signalling proteins used by immune and other cells to communicate.

The study’s achieved-status selection and one-sided statistical testing limit causal interpretation. Its reported percentage, units and one figure-versus-text significance statement also contain inconsistencies. Those details cannot be silently repaired by choosing the more favourable result. The useful bounded observation is receptor-output discordance in a weak clinical design, not a proven threshold or an optimal blood target.

Kariuki and colleagues studied primary monocytes from 20 healthy donors and measured broad patterns of gene transcription. Active vitamin D altered the response to an inflammatory stimulus: selected antimicrobial and autophagy-related programmes increased while selected inflammatory programmes decreased. Autophagy is a cellular recycling process. Changes in related gene patterns suggest pathways for investigation; they do not establish improved recycling activity, antimicrobial function or disease protection.

The donor sample was small, and the analysis tested many molecular features. Additional published binding datasets were integrated under different experimental conditions and do not constitute new donor replications. The study also does not justify ancestry-specific treatment claims. These findings add detail to the coordinated biology described in Vitamin D and Immunity, while leaving functional and clinical questions separate.

Peptide signals, protein and function are not interchangeable

Antimicrobial peptides are small proteins involved in local defence and signalling. Cathelicidin is produced in a precursor form and can be processed into an active peptide. An assay that recognises both forms cannot be interpreted as measuring only the active product. The overview Vitamin D and Antimicrobial Peptides explains the general role; the studies below show why the exact assay and sampling compartment matter.

Hertting and colleagues studied human bladder tissue and epithelial-cell models, alongside supplementation observations in eight postmenopausal women, five of whom completed biopsies. Circulating peptide and unstimulated tissue did not simply rise with vitamin D status. Local stimulation and tissue context affected the observed response. The antibody used recognised precursor and cleaved peptide, which limits claims about the active form alone.

The human component was small and uncontrolled. The report’s oral compound description was not independently resolved, so this review does not identify it as a particular vitamin D formulation. The selected evidence is restricted to expression and local-response findings; the paper’s separate functional figure is not used here. No conclusion about prevention of urinary infection follows from these observations.

A prenatal trial separates peptide amount from defence

Raqib and colleagues analysed a substudy of a randomised prenatal vitamin D3 trial. Adequate samples were available from 129 mother: cord pairs, with smaller subsets for individual outcomes. The text describes allocation as 65 and 64, while the baseline table headings give 63 and 66. That inconsistency remains part of the source’s limitations. The functional subset contained 112 samples, 56 per arm.

Maternal supplementation did not increase the measured circulating or extracellular neonatal peptide and did not improve the measured cellular defence outcome. The apparent intracellular peptide reduction depended on the statistical analysis: a rank-based ratio comparison had P = 0.02, whereas bootstrap inference gave P = 0.15. The title’s wording about suppression therefore needs qualification rather than repetition as an established effect.

Importantly, uncertain peptide reduction was not evidence of impaired defence. Conversely, an unchanged defence assay does not prove that every immune outcome was equivalent. A status-stratified figure was not a randomised dose-response experiment. This study directly challenges the assumption that peptide abundance and function necessarily move together, without establishing clinical benefit or harm for infants.

Airway studies add compartment and comparison limits

Sanders and colleagues followed vitamin D-deficient current smokers in an uncontrolled pilot. Seventeen completed the study from 29 enrolled; nine completers had chronic obstructive pulmonary disease. Native vitamin D3 supplementation raised blood vitamin D status but did not produce a detected rise in cathelicidin measured in blood or lung fluid. Measurements from the two compartments were not interchangeable.

The absence of a placebo group, attrition and small sample mean that a null detection is not proof of zero biological effect. The assay did not isolate only active, cleaved peptide. The study also did not measure antimicrobial function or clinical infection outcomes. Its title refers to 25-hydroxy vitamin D, but the intervention described in the report was native vitamin D3; the distinction is relevant when reading the title alone.

Vargas Buonfiglio and colleagues assessed airway-fluid defence activity in a randomised vitamin D3 trial. The flowchart reports 98 randomised participants, 48 and 50 per arm, but the functional analysis used only 40 samples, 21 and 19. The narrative also reports 105 enrolled and 86 completing the parent study. These are different stages and endpoints, not interchangeable denominators.

The supplemented group showed a change in its laboratory assay, while placebo also improved numerically. Statistical significance within one arm does not establish a significant treatment difference between arms. Exploratory smoking-related observations lacked the relevant treatment-by-smoking interaction test, so they cannot establish a smoker-specific response. The report did not directly measure active-peptide abundance or demonstrate a clinical infection benefit.

The two airway studies therefore answer different questions: one measured peptide abundance in two compartments; the other measured selected functional activity. Their results should not be pooled informally or described as contradicting each other on a single endpoint. The broader physiology of Vitamin D and Mucosal Defence includes tissue barriers, local signals and other defence components that neither assay captures in full.

What this comparison adds

The recognition studies show that vitamin D-related signalling can change selected cellular responses, with different directions across models. The peptide studies show that transcription, precursor or peptide abundance, and laboratory defence are separate outcomes. The human studies add important null and uncertain comparisons to the mechanistic evidence. They do not supply a universal causal numerical activation threshold or demonstrate that supplements prevent infections in the populations considered here.

The evidence is strongest when stated at its measured level. A receptor finding can support a receptor claim; a gene-expression finding can support a transcription claim; and a functional assay can support an assay-specific claim under its comparison and sampling limits. Moving from those observations to clinical protection requires evidence that actually tests that outcome. This is a limitation of inference, not a denial that vitamin D participates in immune biology.

Source access and scope

This is a selected comparative evidence review, not an exhaustive review of every receptor, tissue or infection. Complete principal material and the relevant figures supporting the included claims were inspected. Claims relying only on unavailable supplementary staining, gene tables or other uninspected material are excluded. Hertting’s separate functional figure was not selected; its inclusion here concerns local expression and response only. No experimental operating procedures are reproduced.

Raqib’s allocation discrepancy and analysis-sensitive peptide result, Ojaimi’s selected follow-up analyses and Vargas’s functional-subset selection remain explicit. Related publications from a parent trial are not counted as independent studies. Several early mechanistic papers share a research programme, which also limits claims of independent replication. Publication identities and indexed correction records were checked on 4 November 2026; this bounded check does not certify that every possible later notice has been found.

The reviewed work supports an account of conditional immune responses. It does not determine a personal vitamin D dose, a preventive blood target or a replacement for clinical care.

Sources

Convergence of IL-1β and VDR Activation Pathways in Human TLR2/1-Induced Antimicrobial Responses. Liu PT et al.. PLoS ONE. 2009;4(6):e5810. DOI: 10.1371/journal.pone.0005810. PMID: 19503839.

Vitamin D Induction of the Human Antimicrobial Peptide Cathelicidin in the Urinary Bladder. Hertting O et al.. PLoS ONE. 2010;5(12):e15580. DOI: 10.1371/journal.pone.0015580. PMID: 21179490.

Related reading

Original sources

Source

Cell‐type‐specific modulation of innate immune signalling by vitamin D in human mononuclear phagocytes

Vitamin D is widely reported to inhibit innate immune signalling and dendritic cell (DC) maturation as a potential immunoregulatory mechanism.

Publication details

Cell-type-specific modulation of innate immune signalling by vitamin D in human mononuclear phagocytes. Kundu R et al.. Immunology. 2017;150(1):55 to 63. Published online2016. DOI: 10.1111/imm.12669. PMID: 27608289.

Read more →
Source

Effect of vitamin D3 on the antimicrobial activity of human airway surface liquid: preliminary results of a randomised placebo-controlled double-blind trial

Published in Vargas Buonfiglio LG et al.. BMJ Open Respir Res (2017).

Publication details

Effect of vitamin D3 on the antimicrobial activity of human airway surface liquid: preliminary results of a randomised placebo-controlled double-blind trial. Vargas Buonfiglio LG et al.. BMJ Open Respir Res. 2017;4(1):e000211. DOI: 10.1136/bmjresp-2017-000211. PMID: 28883932.

Read more →
Source

Calcitriol May Down-Regulate mRNA Over-Expression of Toll-Like Receptor-2 and -4, LL-37 and Proinflammatory Cytokines in Cultured Human Keratinocytes

Published in Jeong MS, Kim JY, Lee HI, Seo SJ. Ann Dermatol (2014).

Publication details

Calcitriol May Down-Regulate mRNA Over-Expression of Toll-Like Receptor-2 and -4, LL-37 and Proinflammatory Cytokines in Cultured Human Keratinocytes. Jeong MS, Kim JY, Lee HI, Seo SJ. Ann Dermatol.2014;26(3):296 to 302. DOI: 10.5021/ad.2014.26.3.296. PMID: 24966627.

Read more →